Evaluation of dorzolamide/timolol fixed combination therapy for the patients who need more IOP reduction under PG analogues

Evaluation of dorzolamide/timolol fixed combination therapy for the patients who need more IOP reduction under PG analogues - Evaluation of dorzolamide/timolol fixed combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004596

Enrollment

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angle glaucoma, ocular hypertension

Interventions

Additive administration of dorzolamide/timolol fixed combination therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) primary open angle glaucoma, ocular hypertension 2) inadequate IOP reduction under PG drugs for more than 2 months

Exclusion criteria

Exclusion criteria: 1) patients who received any surgical therapy within the past 3 months (incl. laser surgery) 2) difficult to measure IOP with GAT 3) difficult to check the fundus due to the corneal opacity or cataract 4) any patients who are expected to receive any surgical procedures during the study periods 5) contraindication of beta blockers or dorzolamide 6) any allergic history to the timilol or dorzolamide 7) women who are under pregnant or lactation period 8) any one who is considered to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
intraocular pressure, ocular and general side effects	—

Countries

Japan

Contacts

Public ContactKazuhiko Mori, Morio Ueno, Yoko Ikeda

Kyoto Prefectural University of Medicine Department of Ophthalmology

kmori@koto.kpu-m.ac.jp075-251-5575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026